NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
(“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, has been invited to speak at the Precision EV Forum 2025, being held October 27–28 in Cambridge, UK. Her participation underscores growing global recognition of NurExone’s leadership in developing exosome therapies and in helping define the regulatory path for this emerging field.
Dr. Sarel will present “Regulatory Challenges in the Clinical Development of ExoPTEN: MSC EVs Loaded with PTEN-siRNA” on October 28, followed by a panel discussion on how developers of exosome therapeutics can better approach regulatory approval. The invitation reflects strong international interest in NurExone’s lead program, ExoPTEN, a drug under development that combines regenerative and anti-inflammatory mechanisms to repair Central Nervous System damage.
“The Orphan Drug Designation granted to ExoPTEN in acute spinal cord injury opened the door to early and constructive discussions with the FDA, where we have built an open, data-driven relationship focused on both innovation and patient safety,” said Dr. Ina Sarel, Director of Clinical and Regulatory Affairs at NurExone.
ExoPTEN is designed to address significant unmet needs and critical indications in central nervous system repair, including acute spinal cord injury and optic nerve damage associated with glaucoma. In both indications, ExoPTEN has demonstrated the ability to restore nerve function and reduce inflammation in preclinical models.
“Leading industry and regulatory stakeholders are following NurExone’s progress closely, and we are glad to present our work in Cambridge,” said Dr. Lior Shaltiel, CEO of NurExone. “Our strategy combines scientific innovation with regulatory leadership, paving the way for exosome-based therapies to reach clinical and commercial realization.”
The Precision EV Forum 2025, focused on removing barriers to the clinic, will feature global leaders advancing the therapeutic potential of exosomes, including Marcin Jurga, PhD, Chief Scientific Officer of EXO Biologics; Heena Sharma, Associate Research Director at Evox Therapeutics; Julien Branchu, Head of R&D at EverZom; and Gloria Matthews, DVM, PhD, formerly Chief Medical Officer at multiple regenerative medicine companies.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
